Endemic country roadshows

2007
Burkina Faso, Benin, Côte d’Ivoire, Kenya, Mali, Malawi, Mozambique, Senegal, Tanzania, Togo and Uganda

In 2007, MMV’s access team carried out roadshows in a total of 11 countries.

MMV has clearly identified the need to reach out to national endemic country decision makers in order to improve awareness of MMV, the portfolio and the impact of new choices of ACT at country level.

These country roadshows provided an opportunity for MMV to present information about the portfolio, as well as understand country needs for scale up of high quality, low cost anti-malarials in achieving maximum health impact. MMV’s Access team began this process in the summer of 2007 with two road shows in Africa. Additional visits to Cameroon, Ghana, Nigeria and Zambia are planned in 2008. Meetings were set up with the aid of MMV partners and ADAC (Access and Delivery Advisory Committee) members in these countries.

Key Stakeholders contacted during the visits included:

-  Heads of the national malaria control programme
-  Chief pharmacist (responsible for Essential Medicines List)
-  Heads of the national procurement agency
-  Drug regulatory agencies
-  Representatives of international donors
-  Representatives of the international organizations at country level
-  Local representatives of key implementing agencies, NGOs, Research Institutes

National programme managers expressed considerable interest in the opportunity of having several new high-quality ACTs to relieve the malaria burden in their countries. They expressed interest in ensuring that these products could be made widely available through both the public and private sectors.

Endemic country decision makers supported the strategic decisions by MMV to invest in developing drugs to stringent regulatory standards. This would provide a strong clinical dossier for review in endemic countries, and offer reassurance to programme managers about the quality and efficacy of the new products relative to those currently on the market.

The emphasis on continuity - from development to delivery of new products - was a strength which national programme managers and other decision makers appreciated.

Decision makers appreciated investment by MMV in the outreach programme. This will be scaled up as the new products reach regulatory approval. MMV will continue to ensure endemic country stakeholders have access to additional information which could be factored into the decision making process in advance of the new drugs coming to market.